GAITHERSBURG, Sept 11 (Reuters) - A panel of advisers to U.S. health regulators voted on Tuesday to reject a target hemoglobin level for kidney disease patients, a win for drugmakers Amgen (AMGN.O: Quote, Profile, Research) and Johnson & Johnson (JNJ.N: Quote, Profile, Research), which had urged a more liberal approach to treatment.The advisers to the Food and Drug Administration voted against setting a new limit for targeted hemoglobin of 11 grams per deciliter for Amgen’s Aranesp and Epogen and Johnson & Johnson’s Procrit in patients with chronic kidney failure who are on dialysis.
